Avalo Therapeutics' (AVTX) Buy Rating Reiterated at BTIG Research

Key Points

• BTIG Research has reiterated its "buy" rating for Avalo Therapeutics (AVTX) with a price objective of $40.00, indicating a potential upside of 207.22% from the current stock price.
• Other brokerages, including Cowen and TD Cowen, have initiated coverage on Avalo Therapeutics with similar "buy" ratings, contributing to a consensus rating of "Buy" among analysts.
• Avalo Therapeutics has a one-year stock performance range from $3.39 to $16.00, and it missed earnings estimates in its latest quarterly report, posting an EPS of ($1.92) against a forecast of ($1.43).

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report)'s stock had its "buy" rating restated by investment analysts at BTIG Research in a note issued to investors on Monday,Benzinga reports. They presently have a $40.00 price objective on the stock. BTIG Research's price objective suggests a potential upside of 207.22% from the company's current price.

A number of other brokerages also recently commented on AVTX. Cowen initiated coverage on shares of Avalo Therapeutics in a research report on Friday, September 5th. They issued a "buy" rating for the company. TD Cowen started coverage on shares of Avalo Therapeutics in a report on Friday, September 5th. They set a "buy" rating for the company. Cantor Fitzgerald initiated coverage on shares of Avalo Therapeutics in a research report on Friday, August 15th. They set an "overweight" rating for the company. Finally, HC Wainwright upped their price target on shares of Avalo Therapeutics from $15.00 to $25.00 and gave the company a "buy" rating in a research report on Wednesday, September 17th. Nine research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Avalo Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $31.67.

Avalo Therapeutics Price Performance

AVTX opened at $13.02 on Monday. Avalo Therapeutics has a one year low of $3.39 and a one year high of $16.00. The company's 50 day simple moving average is $9.50 and its 200-day simple moving average is $6.67.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($1.92) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.43) by ($0.49). On average, equities analysts anticipate that Avalo Therapeutics will post -19.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Avalo Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in AVTX. Northern Trust Corp purchased a new stake in shares of Avalo Therapeutics during the 4th quarter valued at about $168,000. RWA Wealth Partners LLC purchased a new position in shares of Avalo Therapeutics in the first quarter valued at $2,505,000. Affinity Asset Advisors LLC grew its holdings in shares of Avalo Therapeutics by 19.3% in the first quarter. Affinity Asset Advisors LLC now owns 657,154 shares of the company's stock valued at $5,264,000 after purchasing an additional 106,389 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in shares of Avalo Therapeutics in the first quarter valued at $7,209,000. Finally, ADAR1 Capital Management LLC purchased a new position in shares of Avalo Therapeutics in the first quarter valued at $80,000. Hedge funds and other institutional investors own 87.06% of the company's stock.

About Avalo Therapeutics

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.